



Commercial/Healthcare Exchange PA Criteria

Effective: November 11, 2020

Prior Authorization: Zelnorm

Products Affected: Zelnorm (tegaserod) tablets

Medication Description: Tegaserod is an agonist of serotonin type-4 (5-HT₄) receptors that stimulates the peristaltic reflex and intestinal secretion, inhibits visceral sensitivity, enhances basal motor activity, and normalizes impaired motility throughout the gastrointestinal tract.

Covered Uses: Treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C).

Exclusion Criteria:

1. Patients with a history of myocardial infarction (MI), stroke, transient ischemic attack (TIA), or angina
2. Patients with a history of ischemic colitis or other forms of intestinal ischemia
3. Severe renal impairment (eGFR < 15 mL/min/1.73 m²) or end-stage renal disease
4. Moderate and severe hepatic impairment (Child-Pugh B or C)
5. Patients with a history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions
6. Hypersensitivity to tegaserod

Required Medical Information:

1. Diagnosis
2. Previous therapies tried and failed

Age Restrictions: Patients age \geq 18 years and < 65 years

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria:

Irritable bowel syndrome with constipation (IBS-C)

- A) Patient has a diagnosis of irritable bowel syndrome with constipation (IBS-C); **AND**
- B) Patient has tried and failed treatment with Linzess **AND** Trulance

References:

1. Zelnorm™ tablets, for oral use [prescribing information]. Louisville, KY: Sloan Pharma; March 2019.
2. Zelnorm. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: <http://www.micromedexsolutions.com>. Accessed 21 Oct 2020.

January 2021



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Page 1 of 2

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	10/21/20
2	Update	Removed trial with Amitiza Replaced Amitiza Trial with trulance trial	Other criteria	1/1/2021